Security
Palvella Therapeutics, Inc. Common Stock · PVLA
PVLANASDAQCommon stockCurrentCIK 1583648Updated Oct 29, 2026
Name history
PIERIS PHARMACEUTICALS, INC. · through Dec 12, 2024Marika Inc. · through Dec 18, 2014
PVLA price & chart
Loading TradingView…
NASDAQ:PVLA on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company whose vision is to become the leading rare disease biopharmaceutical company focused on developing and, if approved, commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases, for which there are no FDA approved therapies. We intend to leverage our versatile QTORIN™ platform to treat these patients. The QTORIN platform is designed to generate new therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of rare, genetic skin diseases. Our lead product candidate, QTORIN 3.9% rapamycin anhydrous topical gel, or “QTORIN rapamycin”, is in clinical development for two of these diseases: microcystic lymphatic malformations, or “microcystic LM”, and cutaneous venous malformations. QTORIN rapamycin contains the active pharmaceutical ingredient rapamycin, also known as sirolimus, which is an inhibitor of mammalian target of rapamycin, or “mTOR”, a kinase that plays a key role in cell growth and proliferation. The QTORIN platform is novel and has only generated one program to date, QTORIN rapamycin, and clinical evidence to support this candidate is preliminary and limite…
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 66,937,000Source | 20,522,000Source | 253,510,000Source | 73,747,000Source | 25,051,000Source | 263,759,000Source | 79,439,000Source | 29,497,000Source | 59,559,000Source | 88,234,000Source | 38,680,000Source | 95,490,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 16,992,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 63,567,000Source | 19,363,000Source | 187,803,000Source | 70,433,000Source | 19,731,000Source | 206,394,000Source | 75,626,000Source | 19,084,000Source | 57,982,000Source | 83,602,000Source | 17,396,000Source | 38,635,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 0Source | 373,000Source | — | 0Source | 1,485,000Source | — | 0Source | 1,842,000Source | 0Source | 358,000Source | 572,000Source | 5,810,000Source |
| Assets, CurrentUSD | 66,937,000Source | — | 253,028,000Source | 73,747,000Source | — | 263,231,000Source | 79,439,000Source | — | 58,987,000Source | 88,234,000Source | 38,680,000Source | 73,424,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,154,000Source | 280,000Source | 2,444,000Source | 1,336,000Source | 649,000Source | 1,378,000Source | 1,835,000Source | 2,972,000Source | 1,005,000Source | 2,296,000Source | 4,087,000Source | 8,445,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 482,000Source | — | — | 528,000Source | — | — | 572,000Source | — | — | 3,705,000Source |
| Other Assets, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 1,369,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 28,255,000Source | — | 36,643,000Source | 25,967,000Source | — | 31,446,000Source | 23,862,000Source | — | 31,576,000Source | 25,627,000Source | 11,922,000Source | 67,561,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 11,000Source | 1,000Source | 14,000Source | 11,000Source | 1,000Source | 14,000Source | 11,000Source | 1,000Source | 12,000Source | 11,000Source | 98,000Source | 74,000Source |
| Additional Paid in CapitalUSD | 161,303,000Source | 342,916,000Source | 389,851,000Source | 159,271,000Source | 342,586,000Source | 383,421,000Source | 157,489,000Source | 342,165,000Source | 163,338,000Source | 156,328,000Source | 341,596,000Source | 318,530,000Source |
| Retained Earnings (Accumulated Deficit)USD | -122,736,000Source | -326,333,000Source | -173,087,000Source | -111,391,000Source | -323,446,000Source | -151,217,000Source | -101,920,000Source | -319,856,000Source | -135,450,000Source | -93,735,000Source | -314,964,000Source | -290,421,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 104,000Source | -316,000Source | 89,000Source | -111,000Source | -436,000Source | 95,000Source | -3,000Source | -346,000Source | 83,000Source | 3,000Source | 28,000Source | -254,000Source |
| Stockholders' Equity Attributable to ParentUSD | 38,682,000Source | -87,404,000Source | 216,867,000Source | 47,780,000Source | -80,828,000Source | 232,313,000Source | 55,577,000Source | -76,873,000Source | 27,983,000Source | 62,607,000Source | 26,758,000Source | 27,929,000Source |
| Liabilities and EquityUSD | 66,937,000Source | 20,522,000Source | 253,510,000Source | 73,747,000Source | 25,051,000Source | 263,759,000Source | 79,439,000Source | 29,497,000Source | 59,559,000Source | 88,234,000Source | 38,680,000Source | 95,490,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 10,312,000Source | 4,254,000Source | 11,947,000Source | 9,616,000Source | 6,346,000Source | 9,115,000Source | 8,983,000Source | 7,533,000Source | 11,344,000Source | 12,038,000Source | 11,922,000Source | 36,583,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | 217,000Source | — | — | 209,000Source | — | — | 202,000Source | — | 0Source | — |
| Accounts Payable, CurrentUSD | 3,481,000Source | 801,000Source | 6,785,000Source | 4,557,000Source | 969,000Source | 5,443,000Source | 4,441,000Source | 1,518,000Source | 4,595,000Source | 4,586,000Source | 3,372,000Source | 4,154,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 318,000Source | — | — | 375,000Source | — | — | 431,000Source | — | 0Source | 12,244,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 19,400,000Source | 250,600,000Source | — | 19,700,000Source | — | — | 19,100,000Source | — | — | 26,400,000Source | 59,200,000Source |
| Short-term InvestmentsUSD | — | 0Source | 62,781,000Source | — | 0Source | 55,459,000Source | — | 0Source | — | — | 8,970,000Source | 20,534,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 1,904,000Source | 2,770,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,376,000Source | 1,094,000Source | 6,401,000Source | 830,000Source | 3,349,000Source | 4,402,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | -358,000Source | -387,000Source | — | -5,307,000Source | 2,624,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -10,864,000Source | -6,768,000Source | -25,006,000Source | -10,840,000Source | -53,819,000Source | -59,932,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -55,440,000Source | 0Source | — | — | 12,002,000Source | -21,236,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 171,000Source | 1,041,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 214,731,000Source | -1,202,000Source | -660,000Source | 87,089,000Source | 19,795,000Source | 7,214,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 148,412,000Source | -7,976,000Source | -25,620,000Source | 76,252,000Source | -21,239,000Source | -79,129,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -15,000Source | -6,000Source | 46,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,790,000Source | 199,000Source | 5,155,000Source | 1,433,000Source | 3,376,000Source | 1,094,000Source | 6,401,000Source | 830,000Source | 3,349,000Source | 4,402,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 19,400,000Source | 250,600,000Source | — | — | — | — | — | 26,400,000Source | 59,200,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | 0Source | — | — | — | — | — | — | -100,000Source | 400,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | 1,800,000Source | 2,300,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | 0Source | -568,000Source | — | — | — | — | 0Source | 1,100,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| General and Administrative ExpenseUSD | — | — | 3,649,000Source | 1,880,000Source | 8,932,000Source | 4,132,000Source | 5,521,000Source | 3,797,000Source | 15,761,000Source | 5,944,000Source | 16,853,000Source | 16,394,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,345,000Source | -6,775,000Source | -21,870,000Source | -9,471,000Source | -15,767,000Source | -8,185,000Source | -41,715,000Source | -17,434,000Source | -24,543,000Source | -33,277,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -11,345,000Source | -6,969,000Source | — | -9,471,000Source | — | -8,185,000Source | — | -17,434,000Source | — | — |
| Operating ExpensesUSD | — | — | 10,177,000Source | 5,062,000Source | 21,405,000Source | 9,250,000Source | 14,855,000Source | 7,871,000Source | 38,602,000Source | 14,095,000Source | 72,566,000Source | 69,376,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 34,000Source | -20,000Source | -8,000Source | 561,000Source | -32,000Source | 224,000Source | 727,000Source | 511,000Source | -250,000Source | 1,303,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 22,835,000Source | 48,395,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 230,000,000Source | 0Source | — | — | 19,729,000Source | 6,922,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | — | — | 35,008,000Source | 28,200,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 956,000Source | 67,000Source | 763,000Source | — | 0Source | 95,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | — | — | 53,000Source | 376,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | 0Source | — | — | — | — | — | — | 38,711,000Source | 25,469,000Source |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | -82,000Source | -75,000Source | -114,000Source | -118,000Source | -116,000Source | -75,000Source | -394,000Source | -633,000Source | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | -30,000Source | 0Source | 4,000Source | 0Source | — | — | 74,000Source | -73,000Source |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Depreciation, Amortization and Accretion, Net | — | — | — | — | — | — | — | — | — | — | — | — |
| Gain (Loss) on Disposition of Assets | — | — | — | — | — | — | — | — | — | — | — | — |
| Payments of Financing Costs | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source | — | — | — | — | — | — | 42,810,000Source | 25,902,000Source |
| Operating Income (Loss)USD | — | — | -10,177,000Source | -5,062,000Source | -21,405,000Source | -9,250,000Source | -14,855,000Source | -7,871,000Source | -38,602,000Source | -14,095,000Source | -29,756,000Source | -43,474,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 34,000Source | -20,000Source | -8,000Source | 561,000Source | -32,000Source | 224,000Source | 727,000Source | 511,000Source | -250,000Source | 1,303,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -11,345,000Source | -6,775,000Source | -21,870,000Source | -9,471,000Source | -15,767,000Source | -8,185,000Source | -41,715,000Source | -17,434,000Source | -24,544,000Source | -33,277,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,345,000Source | -6,775,000Source | -21,870,000Source | -9,471,000Source | -15,767,000Source | -8,185,000Source | -41,715,000Source | -17,434,000Source | -24,543,000Source | -33,277,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.03Source | -3.94Source | -1.52Source | -0.86Source | -1.2Source | -0.74Source | -3.71Source | -7.83Source | -0.27Source | -0.45Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.03Source | -3.94Source | -1.52Source | -0.86Source | -1.2Source | -0.74Source | -3.71Source | -7.83Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 11,064,282Source | 1,770,167Source | 14,356,219Source | 11,052,741Source | 13,085,271Source | 11,013,697Source | 11,251,250Source | 2,225,934Source | 90,064,000Source | 74,172,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 11,064,282Source | 1,770,167Source | 14,356,219Source | 11,052,741Source | 13,085,271Source | 11,013,697Source | 11,251,250Source | 2,225,934Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | 0Source | -568,000Source | — | — | — | — | 0Source | 1,100,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 3,649,000Source | 1,880,000Source | 8,932,000Source | 4,132,000Source | 5,521,000Source | 3,797,000Source | 15,761,000Source | 5,944,000Source | 16,853,000Source | 16,394,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -41,779,000Source | — | -9,818,000Source | -11,765,000Source |
| Interest Expense, DebtUSD | — | — | 0Source | 220,000Source | — | 0Source | — | — | 0Source | 430,000Source | — | — |
| Interest Income (Expense), NetUSD | — | — | 628,000Source | 187,000Source | 1,965,000Source | 690,000Source | 1,073,000Source | 752,000Source | 2,590,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | 169,000Source | — | — | — | — | — | — | 1,851,000Source | 721,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -11,345,000Source | -6,969,000Source | — | -9,471,000Source | — | -8,185,000Source | — | -17,434,000Source | — | — |
| Operating ExpensesUSD | — | — | 10,177,000Source | 5,062,000Source | 21,405,000Source | 9,250,000Source | 14,855,000Source | 7,871,000Source | 38,602,000Source | 14,095,000Source | 72,566,000Source | 69,376,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 0Source | 194,000Source | — | 0Source | — | 0Source | — | 0Source | — | — |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | — | — | 53,000Source | 376,000Source |
| Research and Development ExpenseUSD | — | — | 6,528,000Source | 3,182,000Source | 12,473,000Source | 5,118,000Source | 9,334,000Source | 4,074,000Source | 22,841,000Source | 8,151,000Source | 41,801,000Source | 52,982,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | 0Source | — | — | — | — | — | — | 38,711,000Source | 25,469,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
Offerings
Registration 333-292544
Registration 333-284093
Filing attachments
pvla-ex99_1.htm · 8-K · 2026-10-28
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an estimated more than 30,000 diagnosed children and adults in the U.S. Phase 3 SELVA study achieved highly statistically significant results across all six prespecified efficacy endpoints (all p<0.001), with 95% of participa…
Read attachment ↗pvla-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 pvla-ex99_1.htm EX-99.1 EX-99.1 Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned standalone U.S. commercial launch of QTORIN™ rapamycin for microcystic lymphatic malformations in the first half of 2027, if approved Initiat…
Read attachment ↗pvla-ex99_2.htm · 8-K · 2026-08-04
EX-99.2 3 pvla-ex99_2.htm EX-99.2 First-in-disease therapies for patients with rare diseases Q2 2026 Financial Results & Corporate Update August 4, 2026 Forward Looking Statements This presentation contains forward-looking statements of Palvella Therapeutics, Inc. (“the Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as “ma…
Read attachment ↗pvla-ex99_1.htm · 8-K · 2026-07-14
EX-99.1 2 pvla-ex99_1.htm EX-PALVELLA THERAPEUTICS CORPORATE PRESENTATION - JULY 2026 First-in-disease therapies for patients with rare diseases Corporate Presentation July 2026 Forward Looking Statements This presentation contains forward-looking statements of Palvella Therapeutics, Inc. (“the Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identi…
Read attachment ↗pvla-ex99_1.htm · 8-K · 2026-05-20
EX-99.1 2 pvla-ex99_1.htm PRESS RELEASE ISSUED BY PALVELLA THERAPEUTICS, INC. ON MAY 20, 2026 EX-99.1 Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations In SELVA Phase 3 study, 100% of participants (13/13) aged 6 - 11 years were rated as “Much Improved” (+2) or “Very Much Improved” (+…
Read attachment ↗pvla-ex99_1.htm · 8-K · 2026-05-15
EX-99.1 2 pvla-ex99_1.htm PRESS RELEASE ISSUED BY PALVELLA THERAPEUTICS, INC. ON MAY 15, 2026 EX-99.1 Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology 100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-…
Read attachment ↗